Compare GEG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEG | ACET |
|---|---|---|
| Founded | 1994 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.9M | 71.3M |
| IPO Year | N/A | N/A |
| Metric | GEG | ACET |
|---|---|---|
| Price | $2.50 | $8.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $136.00 |
| AVG Volume (30 Days) | 92.2K | ★ 196.6K |
| Earning Date | 02-04-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $23,112,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.00 | ★ N/A |
| Revenue Growth | ★ 24.82 | N/A |
| 52 Week Low | $1.76 | $7.15 |
| 52 Week High | $3.51 | $17.76 |
| Indicator | GEG | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 48.95 | 98.12 |
| Support Level | $2.38 | $0.47 |
| Resistance Level | $2.50 | $0.52 |
| Average True Range (ATR) | 0.11 | 0.15 |
| MACD | -0.01 | 0.78 |
| Stochastic Oscillator | 51.02 | 94.27 |
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.